Can brexpiprazole (Rexulti) be co‑prescribed with escitalopram (Lexapro) in an adult patient without contraindications such as serotonin syndrome, cardiac arrhythmias, or severe hepatic impairment?

Yes, Rexulti (brexpiprazole) can be safely co-prescribed with Lexapro (escitalopram) in adults without contraindications.

This combination is FDA-approved and clinically established. Brexpiprazole is specifically approved as adjunctive therapy to antidepressants, including escitalopram, for major depressive disorder 1. The combination has demonstrated superior efficacy compared to antidepressant monotherapy in clinical trials 2, 3.

Mechanism and Rationale

The combination works synergistically through complementary mechanisms:

• Brexpiprazole acts as a serotonin-dopamine activity modulator with partial D2/5-HT1A agonism and 5-HT2A antagonism
• Escitalopram selectively inhibits serotonin reuptake
• Together, they potentiate both NMDA and AMPA receptor-mediated glutamatergic transmission in the prefrontal cortex via dopamine D1 receptor-dependent mechanisms 4

Preclinical studies confirm synergistic antidepressant effects, with the combination reducing immobility time in forced swim tests more than either agent alone 5.

Safety Considerations

Serotonin Syndrome Risk

While combining serotonergic agents theoretically increases serotonin syndrome risk, caution rather than contraindication applies 6. The guidelines state that when combining two non-MAOI serotonergic drugs:

• Start the second agent at a low dose
• Increase slowly
• Monitor closely for symptoms in the first 24-48 hours after dosage changes 6

Key point: Serotonin syndrome is primarily associated with MAOIs combined with other serotonergic agents. The brexpiprazole-escitalopram combination does not involve MAOIs and has been extensively studied without significant serotonin syndrome reports 1, 2, 3.

Cardiac Considerations

Escitalopram has the least effect on CYP450 enzymes among SSRIs and lower propensity for drug interactions 6. However, citalopram/escitalopram can prolong QTc interval, particularly at doses exceeding 40 mg/day 6, 7.

Brexpiprazole does not significantly affect cardiac conduction based on FDA labeling 1.

Recommendation: Obtain baseline ECG if cardiac risk factors present (long QT syndrome, electrolyte abnormalities, concurrent QT-prolonging medications). Avoid escitalopram doses >40 mg/day, especially in patients >60 years 6.

Drug-Drug Interactions

Brexpiprazole exhibits weak inhibitory effects on CYP enzymes and transporters at therapeutic concentrations 8. No clinically significant pharmacokinetic interactions are expected between brexpiprazole and escitalopram 1, 8.

Dosing Algorithm

For adjunctive brexpiprazole to escitalopram:

1. Establish escitalopram first: Ensure patient has been on adequate antidepressant trial (typically 4-8 weeks at therapeutic dose)
2. Initiate brexpiprazole: Start 0.5-1 mg daily for days 1-4, then 2 mg daily on days 5-7
3. Target dose: 2-3 mg daily based on response and tolerability 1
4. Titration: Increase to 3 mg after 1 week at 2 mg if needed

Dose adjustments required for:

• CYP2D6 poor metabolizers: Maximum 2 mg/day (or 3 mg/day for MDD) 1
• Moderate-severe hepatic impairment: Maximum 2 mg/day (or 3 mg/day for MDD) 1
• Renal impairment (CrCl <60 mL/min): Maximum 2 mg/day (or 3 mg/day for MDD) 1
• Concurrent strong CYP3A4 or CYP2D6 inhibitors: Reduce brexpiprazole dose by 50% 1

Monitoring Protocol

Baseline:

• BMI, waist circumference, blood pressure
• Fasting glucose/HbA1c, lipid panel
• ECG if cardiac risk factors present
• Assess for akathisia/extrapyramidal symptoms

Follow-up:

• Week 1-2: Monitor for behavioral activation, serotonin syndrome symptoms (confusion, agitation, tremor, hyperreflexia, autonomic instability)
• Week 4: Recheck fasting glucose
• Ongoing: Weight, metabolic parameters, movement disorders 9, 1

Common Pitfalls

1. Premature discontinuation: Patients may experience akathisia early in treatment. This is dose-related and often resolves with dose reduction or time 1
2. Inadequate antidepressant trial: Ensure escitalopram has been optimized before adding brexpiprazole
3. Overlooking metabolic effects: Brexpiprazole causes weight gain and metabolic changes; proactive monitoring and metformin co-prescription may be warranted 9, 1
4. Ignoring CYP2D6 status: Poor metabolizers require dose reduction 1

Contraindications

Absolute:

• Known hypersensitivity to brexpiprazole 1
• Concurrent MAOI use (within 14 days) 6

Relative caution:

• Congenital long QT syndrome
• Uncontrolled cardiac arrhythmias
• Severe hepatic/renal impairment (requires dose adjustment, not contraindication)
• History of seizures (use cautiously) 6, 1

This combination is well-established, FDA-approved, and supported by robust clinical trial data demonstrating both efficacy and tolerability 2, 3. The key is appropriate patient selection, dose titration, and monitoring.